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Hydrogen bonding penalty upon ligand binding
Abstract
Ligand binding involves breakage of hydrogen bonds with water molecules and formation of new
hydrogen bonds between protein and ligand. In this work, the change of hydrogen bonding energy in the
binding process, namely hydrogen bonding penalty, is evaluated with a new method. The hydrogen
bonding penalty can not only be used to filter unrealistic poses in docking, but also improve the
accuracy of binding energy calculation. A new model integrated with hydrogen bonding penalty for free
energy calculation gives a root mean square error of 0.7 kcal/mol on 74 inhibitors in the training set and
of 1.1 kcal/mol on 64 inhibitors in the test set. Moreover, an application of hydrogen bonding penalty
into a high throughput docking campaign for EphB4 inhibitors is presented, and remarkably, three novel
scaffolds are discovered out of seven tested. The binding affinity and ligand efficiency of the most
potent compound is about 300 nM and 0.35 kcal/mol per non-hydrogen atom, respectively.
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Introduction
Hydrogen bonding is an exchange reaction whereby the
hydrogen bond donors and acceptors of the free protein and
ligand break their hydrogen bonds with water and form new ones
in the protein-ligand complex [1,2,3]. About thirty years ago,
Wilkinson and coworkers found mutation of Cys-35 in Tyrosyl-
tRNA synthetase to Ser-35 causes poorer ATP binding and
catalysis although the hydroxyl group of serine forms far stronger
hydrogen bonds than does the thiol group of cysteine [1]. Analysis
of the hydrogen bonding geometry revealed that a hydrogen bond
of Ser-35 is at least 0.5 A˚ longer than the optimum. Accordingly,
Ser-35 would have to lose a good hydrogen bond with a bound
water molecule to form this weak hydrogen bond with ATP in the
enzyme-substrate complex, and thus the mutant shows poorer
binding and catalysis. Therefore, enthalpic loss in hydrogen
bonding could take place upon ligand binding if not compensated
by formation of good hydrogen bonds between the protein and
ligand.
Virtual screening has emerged as an efficient tool in drug
discovery from lead identification to optimization and beyond
[4,5]. However, scoring functions that model the solvent
environment as a continuum [6,7] are still grossly inaccurate [8].
The role of individual waters can be critical in predication of
binding affinities, and continuum models often provide poor
results in treating bound waters in a confined cavity [9]. Glide
docks explicit waters into the binding site and measures the
exposure of polar/charged groups to the explicit waters. When a
polar/charged ligand or protein group is judged to be inade-
quately solvated, a desolvation penalty is assessed [9,10]. By
contrast, most other scoring functions [11] do not properly take
into account the enthalpic loss of hydrogen bonding upon ligand
binding. Incorporation of bound water molecules into molecular
docking was suggested for improvement of accuracy [12]. On the
other hand, in high-throughput molecular docking campaigns a
significant part of binding poses are rather unrealistic, e.g. burial of
polar atoms in hydrophobic sites, and thus discarding them at an
early stage is desirable. Filters such as van der Waals efficiency
based on arbitrary cutoff are often used to remove poses that
unlikely bind [13]. However, it seems lack of a reliable and
efficient filter with transferable cutoff among different proteins.
Protein kinases play an important role in cell-signaling pathways
regulating a variety of cellular functions. Dysregulation of kinase
activity has been implicated in pathological conditions ranging
from neuronal disorders to cellular transformation in leukemia
[14]. The tyrosine kinase erythropoietin producing human
hepatocellular carcinoma receptor B4 (EphB4) is involved in
cancer related angiogenesis [15]. So far, two high-throughput
virtual screening campaigns have been reported, with two scaffolds
identified in the low micromolar range [13,16]. Highly potent
EphB4 inhibitors have been developed via chemical synthesis
[17,18,19]. The marketed drug dasatinib, with Abl1 and Src as
primary targets, also shows a very high affinity to Eph kinases [20].
Here, we report a new approach to calculate hydrogen bonding
penalty (HBP) associated with ligand binding. HBP is further
integrated into a binding energy calculation, and the fitted
parameter of 1.7 kcal/mol is consistent with the estimate of
contribution by formation of one neutral hydrogen bond ranging
from 0.5 to 1.5 kcal/mol [21]. Moreover, statistics of HBP in
kinase crystal structures and an application in a high-throughput
docking campaign is presented.
Methods
Binding of a ligand to a protein involves the breakage of
hydrogen bonds with water molecules and formation of new
hydrogen bonds between the protein and ligand, which can be
described by the following equation [21] by using one pair of
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donor (D) and acceptor (A):
D   OH2zA   HOH<D   AzHOH   OH2 ð1Þ
Based on hydrogen bonding being an exchange reaction [1,21,22],
its energy can be described using normalized weights:
EHB{unbound~½(wDzwO{H2O)z(wAzwH{H2O)  EHB ð2Þ
EHB{bound~½fhb  (wDzwA)z(wO{H2OzwH{H2O)  EHB ð3Þ
wherein, wD and wA is the hydrogen bonding weight of a donor or
acceptor, respectively, fhb stands for the fraction of hydrogen
bonding relative to that of an optimum geometry, and EHB is unit
hydrogen bonding energy. Hydrogen bonds with water are
assumed to be in the optimum geometry. HBP (pHB) associates
with ligand binding is then described as
pHB~(1{fhb)  (wDzwA) ð4Þ
Probing hydrogen bonding status
Oxygen and nitrogen atoms in double or triple bonds are
regarded as hydrogen bond acceptors, and hydrogen atoms
bonded to oxygen, nitrogen or sulfur atoms are regarded as
hydrogen bond donors. The existence of C—H...O hydrogen
bonds has been confirmed by neutron diffraction data on organic
compounds [23]. Analysis of 100 kinase crystal structures
complexed with small molecule inhibitors at a resolution of at
least 2.5 A˚ gives 64 short C—H...O interactions, showing typical
hydrogen bonding features (Figure S1).
Each hydrogen bond donor or acceptor at the binding
interface is firstly checked whether it forms hydrogen bond with
water molecules. For this purpose, an optimum solvation radius
(rsol) is defined for each donor/acceptor and if a water molecule
can be placed within 0.15 A˚ of the rsol no penalty is applied.
Here, 2.8 and 2.9 A˚ are used as rsol for any oxygen and nitrogen,
respectively, which were derived from an analysis of 397 crystal
structures with X-ray resolutions below 1.0 A˚ (Figure S2). The rsol
of polar hydrogen is 1.9 A˚ (except 2.15 A˚ for H bonded to sulfur),
which is the difference between the rsol of nitrogen and the bond
length [24] of N—H. The rsol of other atom types are listed in
Figure 1 and the values are mainly adapted based on the van der
Waals radii of Bondi [25]. Details of probing hydrogen bonds
with water were described in File S1. In case of not forming
hydrogen bonds with water, the possibility of forming hydrogen
bonds between the protein and ligand (including intra-molecular
hydrogen bonds) is further checked and penalty (pHB) is then
calculated.
Fraction of hydrogen bonding
Similar to the strategy of evaluating hydrogen bonding energy
in LUDI [26], the following equations are used to calculate the
fraction of hydrogen bonding (fhb) to that of an optimum
geometry.
fhb(r,h) ~ f (r):f (h) ð5Þ
Figure 1. Hydrogen bonding weights and solvation radii of different atom types.
doi:10.1371/journal.pone.0019923.g001
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f (r) ~
1 if rƒ2:0
1{0:5  (r{2:0) if 2:0vrƒ2:8
0 if rw2:8
8><
>:
ð6Þ
f (h) ~
1 if h§150o
4:0  ({ cos h)0:25{2:86 if 110oƒhv150o
0 if hv110o
8><
>:
ð7Þ
wherein, r is the distance between the hydrogen atom and the
acceptor and h is the angle centered at hydrogen among donor,
hydrogen and acceptor. The equation to calculate f(r) and f(h) as
well as the upper and lower limit in r and h are derived from the
calculation using density functional theory [27]. In case of one
hydrogen atom is shared by two acceptors or one acceptor
interacting with two donors, the fhb for the corresponding donor/
acceptor is additive but with 1 as the upper limit.
Hydrogen bonding penalty
The HBP at the protein-ligand interface is summarized over
each donor/acceptor as
PHB ~
X
pro,lig
w  (1{
X
fhb) ð8Þ
However, no penalty is applied for protein atoms which are not
water accessible before ligand binding or participate in intra-
molecular hydrogen bonds. Initial guess of hydrogen bonding
weights (w) is based on chemical intuition by considering atomic
partial charge and water solubility of a few small molecules (Table
S1). Empirical weights as proof-of-principle are then optimized
with a trial-and-error procedure according to the fitted parameter
in the binding free energy calibration.
Evaluation of binding free energy
The equation used for fitting the calculated energies to the
experimental free energies of binding (DG=RTln(Kd)) is a three-
parameter model
DG~aDEffzbPHBzc ð9Þ
where, DEff is the interaction energy between the ligand and the
protein calculated by the CHARMm force filed [28] and PHB
stands for HBP. Three parameters a, b, and c are generated with
fitting. DEff is calculated by the following equation:
DEff~DEvdWzDEcoulzDGsolvzDEstrain ð10Þ
where, DEvdW is the intermolecular van der Waals energy, DEcoul
is the intermolecular Coulombic energy in vacuo, DEstrain is the
strain energy of ligand upon binding, and DGsol is the change in
solvation energy of ligand and protein upon binding.
The van der Waals and Coulombic interaction energy are
calculated by subtracting the values of the isolated components from
the energy of the complex with CHARMM [29] and the
CHARMm22 force filed [28]. The van der Waals energy is
calculated using the default nonbonding cutoff of 14 A˚. Coulombic
energy is calculated using infinite cutoff and a dielectric constant of
2.0. The electrostatic solvation energy was calculated by the finite-
difference Poisson approach (FDP) [30] using PBEQmodule [31] in
CHARMM and a focusing procedure with a final grid spacing of
0.25 A˚. The size of the initial grid is determined by considering a
layer of at least 12.5 A˚ around the solute. The dielectric
discontinuity surface was delimited by the van der Waals surface.
The ionic strength is set to zero and the temperature to 300 K. Two
finite-difference Poisson calculations are performed for each of the
three systems (protein, ligand, and protein/ligand complex). The
exterior dielectric constant was set to 78.5 and 2.0 for the first and
second calculation, respectively, while the solute dielectric constant
is 2.0 to take polar fluctuations into account. The solvation energy is
the difference between the two calculations. The strain energy of the
ligand is the energy difference between the bound and global
minimum. Here, the global minimum is the one showing the lowest
EvdW+Ecoul+Ebonded+Gsol among all the poses that have been
minimized outside of the protein.
Twenty-three inhibitors [32] of CDK2 (1H0V), 24 inhibitors
[18] (8 to 32, excluding 30) of EphB4 (2VWX), and 27 uncharged
inhibitors [33] of p38 alpha MAP kinase (3GC7) are used as the
training set. Thirty type II inhibitors [34] of Braf (3II5), 14
charged inhibitors [33] of p38 alpha and another 20 p38 alpha
inhibitors [35] (1YWR) are used as the test set. Protein structures
were taken from the X-ray structure (PDB code indicated in the
brackets) and prepared as described below. Some key physio-
chemical properties of inhibitors are summarized in Figure S3.
Version 4 of AutoDock [36] was used to generate the binding
poses over the conformational search space using the Lamarckian
genetic algorithm. The binding site was determined by 4.0 A˚ away
from any atom of the ligand complexed in the respective protein
structure. The number of energy evaluations was 2,750,000 and the
number of poses was 50. Poses were further clustered using all atom
RMSD cutoff of 0.3 A˚ to remove redundancy and in average 20
cluster representatives were kept. All other parameters were set as
default. A few poses for each inhibitor were also generated by
manual modification of the scaffold present in the respective crystal
structure. All poses were further minimized by CHARMM in the
respective proteins. The protein structure was kept rigid in all steps.
Preparation of protein-ligand complexes
One hundred kinase crystal structures (including 15 different
classes, File S2) complexed with small molecule inhibitors at a
resolution of at least 2.5 A˚ were downloaded from Protein Data
Bank for analysis of HBP. Hydrogen atoms were added according
to the protonation states of chemical groups at pH 7. Partial
charges were then assigned using MPEOE method [37,38]. The
added hydrogen atoms were minimized by the conjugate gradient
algorithm to a RMS of the energy gradient of 0.01 kcal -
mol21 A˚21. During minimization, the electrostatic energy term
was screened by a distance-dependent dielectric of 4r to prevent
artificial deviations due to vacuum effects, and the default
nonbonding cutoff of 14 A˚ was used. Furthermore, the positions
of all heavy atoms were fixed.
Preparation of the compounds library for virtual
screening
The compounds were selected from Zinc library [39].
Preparation included the assignment of CHARMm atom types,
force field parameters [28], and partial charges [37,38], and
energy minimization with a distance dependent dielectric function
using the program CHARMM [29].
Enzymatic assay
In vitro kinase activity was measured using the Panvera Z’lyte
Tyr2 kinase assay PV3191 (Invitrogen) according to the
Hydrogen Bonding Penalty upon Ligand Binding
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manufacturer’s instructions. The reaction assay (10 mL) contained
7.5 ng of EphB4 kinase (Proqinase, Germany), 30 mM ATP, and
5% DMSO. The reaction was performed at room temperature for
1 h.
Results and Discussion
Statistics of hydrogen bonding penalty in kinase
complexes
Small HBPs can be observed for the binding modes of inhibitors
in the X-ray structures. One example is c-Kit tyrosine kinase with
its apo and holo form in complex with Imatinib (PDB codes 1T45
and 1T46). In the apo conformation, donors/acceptors at the ATP
binding site form hydrogen bonds with bound water molecules.
While upon ligand binding, as shown in the holo conformation,
some water molecules are displaced by Imatinib. HBP on the
protein part is close to zero because new hydrogen bonds to the
protein are formed to compensate for the replacement of the water
molecules. However, one nitrogen atom of the Imatinib
pyrimidine ring (N1 of Figure S4) becomes water inaccessible
and does not form a new hydrogen bond, leading to a penalty of 1.
By contrast, the other nitrogen atom (N2 of Figure S4) remains
hydrogen bonding with a nearby bound water molecule and thus
has no penalty.
To check the distribution of HBP values in crystal structures,
100 kinase-ligand complexes are investigated. In this data set, all
the small molecule inhibitors have molecular weights from 200 to
700 g/mol and number of donors or acceptors from 2 to 11 (File
S2). The HBP has been calculated for each of them and the values
are in general small, with 62% smaller than 1 and 36% and 2% in
the range from 1 to 2 and 2.0 to 2.1, respectively (Figure 2 and File
S2). It has also been observed that larger HBPs appear in some X-
ray structures, e.g., the structures of PDB code 3KVX and 1JSV,
and the large values actually originate from poor fitting of small
molecules to the density, a common problem in crystallography
[40] which can be manifested by clash of atoms.
Distribution of HBPs for docked poses of small-molecule inhibitors
is also evaluated. Here, the 138 molecules used in the binding free
energy calibration are docked into the corresponding protein binding
sites with AutoDock. For each molecule, about 20 poses in average
are generated. Then the HBPs and binding energies are calculated
for all the poses. Firstly, the binding pose with the most favorable
binding energy for each molecule (Figure S5) is selected and the
distribution ofHBPs is plotted. As can be observed fromB of Figure 2,
the distribution is similar to that of the 100 kinase complex structures
(A). On the other hand, the distribution of all poses (C) spreads more
widely with the largest HBP being 6.5. Compared with the HBPs in
the crystal structures (A), 2 is a reasonable threshold, and about 50%
of poses with unrealistic binding modes can be filtered out from
further evaluations.
Hydrogen bonding penalty improves the accuracy of
binding energies calculation
Binding energies can be calculated using equation 9 with the
parameters obtained by least-squares fitting on the training data
Figure 2. Distribution of hydrogen bonding penalties for: A)
the binding modes in crystal structures of the 100 kinase
complexes; B) poses with the most favorable calculated
binding energies of the 138 molecules used in binding free
energy calibration; C) all poses of the 138 molecules.
doi:10.1371/journal.pone.0019923.g002
Figure 3. Comparison of the calculated versus experimental
binding energies. A) Training set of 74 inhibitors. R2 = 0.92 and RMS
error = 0.69 kcal/mol; B) Validation set of 64 inhibitors. RMS er-
ror = 1.12 kcal/mol. The blue dots indicated the 14 p38a inhibitors with
one formal charge. The green diagonal line is the ideal line of perfect
prediction. The black diagonals delimit the 1 kcal/mol error region.
doi:10.1371/journal.pone.0019923.g003
Hydrogen Bonding Penalty upon Ligand Binding
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set of the 74 CDK2, EphB4, and p38a inhibitors as following:
DG~0:207  DEffz1:72  PHB{1:17 ð11Þ
The calculated binding energies show high correlation with the
experimental values (R-square of 0.92) and a small RMS error of
0.69 kcal/mol (Figure 3A). Here, the parameter b corresponds to
the unit hydrogen bonding energy. Notably, the fitted value
1.72 kcal/mol is in agreement with the experimental value, e.g.,
breakage of a neutral hydrogen bond resulting in loss of energy
from 0.5 to 1.5 kcal/mol [21]. Moreover, a charged primary
amine or carboxyl group has a hydrogen bonding weight of 1.5 or
2.0, which can lead to a maximal penalty of 2.58 or 3.44 kcal/mol
upon loss of the hydrogen bond/salt bridge. This value also agrees
well with the experimental data (up to 4 kcal/mol) [21]. Hydrogen
bonding weights were further used to rank the strength of
individual hydrogen bonds in DNA base pairs, exhibiting good
compatibility with the previously reported results (File S3).
The fitted model has been validated on a test set including 14
charged p38a inhibitors and 30 type II Braf inhibitors, with an
RMS error of 1.12 kcal/mol (Figure 3B). Moreover, validation
with different kinases shows general transferability of this model
(Table 1). Transferability can be also seen for aspartic protease,
e.g., HIV-1 protease and b-secretase, although a shift of 2.0 kcal/
mol can be observed for the latter. Previously, we reported a two-
parameter LIECE model for kinase inhibitors [13], which is not
transferable for type II kinase inhibitors, HIV-protease or b-
secretase inhibitors. The binding affinities predicted by the two-
parameter LIECE on the 24 type I EphB4 inhibitors show about
25.0 kcal/mol shift compared with the experimental values
(Table S2). Clearly, the incorporation of HBP into the scoring
function improves the general transferability besides the role of
ligand reorganization energy [41].
The derived model includes calculation of solvation energy by
FDP which requires about 6 min on a single Intel 2.8 GHz CPU.
Replacing the FDP approach with a distance-dependent dielectric
model for solvation energy calculation gives similar accuracy for
the neutral inhibitors at a much fast speed (10 seconds). However,
distance-dependent dielectric model can only apply for non-
charged compounds due to inaccurate treatment of the solvation
effect, and also more false positives in a high-throughput virtual
screening are observed. This comparison indicates that accurate
calculation of solvation energies in prediction of binding affinities
is necessary.
Virtual screening for EphB4 inhibitors
In a recent high throughput docking study for EphB4 inhibitors,
ZINC ‘‘leads-now’’ library of about 20 million compounds
Table 1. Further validation of the three-parameter model with kinases and aspartic protease.
Protein PDB code DEff (kcal/mol) PHB DGpred (kcal/mol) DGexp (kcal/mol)
Abl 1OPJ 264.80 1.24 212.45 210.81
Braf 1UWH 257.61 1.27 210.91 210.45
JAK2 3E63 230.18 0.00 27.41 27.91
Lck 2OFV 259.13 0.53 212.51 213.23
JNK3 1PMV 230.16 0.17 27.12 29.31
Ret 2X2L 226.67 0.07 26.58 27.20
EGFR 1XKK 266.60 2.30 211.00 210.91
CSrc 3G5D 252.34 1.64 29.19 212.82
HIV-1 protease 1HIH 265.71 1.49 212.21 211.01
1HPX 265.44 1.43 212.26 212.46
1HXB 261.24 0.95 212.21 213.49
1HXW 272.66 1.41 213.78 214.71
BACE-1 2QMF 273.62 1.56 213.72 211.63
2QP8 268.76 0.47 214.59 211.05
2XFI 271.10 2.36 211.83 210.67
doi:10.1371/journal.pone.0019923.t001
Figure 4. Schematic picture of the high throughput docking
approach. HB stands for hydrogen bond. Met696 and Glu694 are the
two key residues of the hinge loop (see also Figure 6).
doi:10.1371/journal.pone.0019923.g004
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(Mw#350 and cLogP#3.5) was first tailored by a pharmacophore
model to generate a focused library of 103,177 compounds. This
pharmacophore model was specifically designed for EphB4 type I
inhibitors, consisting of a bi-dentate hydrogen bonding pattern
and a conjugate hydrophobic group to be located in the deep ATP
back pocket as well as geometric constraints thereof (H. Zhao,
unpublished results). To our best knowledge, all known type I
EphB4 inhibitors [13,16,17,18] can fulfill this model.
The focused library was docked by AutoDock 4 and about 1
million poses were generated by clustering with a RMSD cutoff of
1.0 A˚. The cluster representatives which do not form a hydrogen
bond to NH of Met696 were further filtered out. The HBP (#2)
was then used to remove unrealistic poses (about 40%). The
remaining poses were further ranked by the predicted binding
energy, and the top about 30% compounds (22,517) with
calculated binding energy smaller than 26 kcal/mol (,50 mM)
were kept. Among them, 1381 compounds forming a hydrogen
bond to Glu694 were selected and can be classified into 80
structural scaffolds. Finally, 7 scaffolds (9 compounds) of them
were purchased for experimental measurements based on visual
inspection of the binding modes, commercial availability and
structural novelty. The procedures used in the virtual screening
are shown in Figure 4. Comparison of the performances between
the proposed and AutoDock 4 scoring function is shown in
Figure S6.
Notably, 4 of the 9 tested compounds show inhibitory activity at
micro-molar to high nano-molar range, with the most active
compound showing IC50 at 300 nM (Figure 5). Interestingly, the
two compound also show a high ligand efficiency [42] of
20.35 kcal/mol per non-hydrogen atom. The predicted binding
mode of compound 3 (Figure 6) is further confirmed by the
preliminary X-ray crystallography (J. Dong, unpublished results).
Figure 5. Identified EphB4 inhibitors by high throughput docking. a All IC50 values are means of two to four dose-response measurements.
doi:10.1371/journal.pone.0019923.g005
Figure 6. Binding mode of compound 3 (carbon atoms in
green) predicted by docking. The intermolecular hydrogen bonds
to the residues at the hinge loop (Glu694 and Met696) and the
gatekeeper (Thr693) are shown by yellow dashed lines. The protein
surface is colored based on atom types with carbon in white, oxygen in
red, and nitrogen in blue. This figure was prepared using PyMOL
(Delano Scientific, San Carlos, CA).
doi:10.1371/journal.pone.0019923.g006
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Conclusion
Hydrogen bonding in biological system is a complex phenom-
enon as water competes with ligand for the hydrogen bonding
sites. Removal of a group that forms a hydrogen bond in
unfavorable geometry actually improves binding [21]. In view of
hydrogen bonding being an exchange reaction [1,21,22], a new
approach is proposed to evaluate the HBP upon ligand binding.
Analysis of the 100 crystal structures indicates the penalty in
general is low, predominantly smaller than 2 for inhibitors. A high
throughput docking case shows HBP can function as an efficient
filter to remove poses that unlikely bind. Incorporation of HBP
into binding free energy calculation can significantly improve the
predictive accuracy and transferability. The fitted parameter of
1.72 kcal/mol means loss of a neutral hydrogen bond would result
in a penalty of from 0.34 to 1.72 kcal/mol in binding energy,
consistent with the experimental data from 0.5 to 1.5 kcal/mol
[21]. Four inhibitors of three scaffolds were discovered out of nine
tested, and the binding affinity and ligand efficiency of the most
potent compound is about 300 nM and 0.35 kcal/mol per non-
hydrogen atom, respectively.
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